Analysis of therapeutic oligonucleotides: Meeting regulatory expectations for drug quality

Chimica Oggi

Volumn 28, Issue 6, 2010, Pages 22-24

  Srivatsa, G Susan ^a   Chan, Ming Fai ^b  

^a ElixinPharma   (United States)

^b Accugent Laboratories Inc   (United States)

Author keywords

Antisense; Aptamers; Oligonucleotide analysis; Purity analysis; Quality control; Regulatory expectations; siRNA

Indexed keywords

EID: 79551698683     PISSN: 0392839X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. R. Kambhampati, Y-Y. Chiu et al., Antisense Res. Dev't, 3, pp. 405-410 (1993).
2. R. Kambhampati, Points to consider for the submission of chemistry, manufacturing and controls (CMC) information in oligonucleotide-based therapeutic drug applications. Center for Drug Evaluation Research, Office of New Drug Quality Assessment, US Food and Drug Administration, DIA Industry and Health Authority Conference on Oligonucleotide Therapeutics (2007).
3. S. L. Beaucage, R.P. Iyer, Tetrahedron, 48, pp. 2223-2311 (1992).
4. ICH Q7A, Good Manufacturing practice guidance for active pharmaceutical ingredients (2001).
5. ICH Q6A, Specifications: Test Procedures and Acceptance criteria for new drug substances and new drug products: Chemical Substances (2007).
6. ICH Q4B, Evaluation and recommendation of pharmacopoeial texts for use in the ICH regions. Annexes 1-10 (2008).
7. G.S. Srivatsa, Regulatory Expectations for the Quality of Oligonucleotide Therapeutics in Handbook of Analysis of Oligonucleotides and Related Products (2011).
8. A.M. Maxam, W. Gilbert, Proc. Natl. Acad. Sci., 74(2), pp. 560-564 (1977).
9. J. Schuette, U. Pieles et al. J. Pharm. Biomed. Anal., 13, pp. 1195-1203 (1995).
10. J.L. Mergny, L. Lacroix, Oligonucleotides, 13(4), pp. 515-537 (2003).
11. G.S. Srivatsa, P. Klopchin et al., J. Pharm. Biomed. Anal., 16, pp. 619-630 (1997).
12. C. Kurata, K. Bradley et al., Bioorg. Med. Chem. Lett., 16, pp. 607-614 (2006).
13. G.S. Srivatsa, M. Batt, et al. J. Chromatogr. A., 680, pp. 469-477 (1994).
14. FDA, Guidance for Industry: Residual solvents in Drug products marketed in the United States (2009).
15. ICH Q3C. Impurities: Residual solvents (1997).
16. USP, General Chapter on Inorganic Impurities: Heavy Metals Stimuli Article (2006).
17. EMEA, Note for Guidance on specification limits for residues of metal catalysts. European Agency for the Evaluation of Medicinal Products (2002).
18. FDA, Guideline on the validation of the LAL test as an end-product endotoxin test for human and animal parenteral drugs, biological products and medical devices (1987).